Format

Send to

Choose Destination
Expert Opin Pharmacother. 2006 May;7(7):917-28.

Pemetrexed in thoracic cancer.

Author information

1
Department of Pulmonary Diseases, University Hospital, Ghent, Belgium.

Abstract

Both lung cancer and mesothelioma are malignancies with increasing incidence, and both are primarily due to inhalation of an external carcinogen. The occurence of both diseases is expected to rise worldwide, although a stabilisation and/or decrease may be anticipated in some developed countries. There are other common similarities to both cancers, including the median age of their patients, the advanced stage at presentation, the outcome and the treatments given. This review focuses on the available evidence of a novel antifolate agent, pemetrexed, in the treatment of both of these thoracic malignancies. Current status, persisting controversies and future developments are discussed.

PMID:
16634714
DOI:
10.1517/14656566.7.7.917
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center